Acesso livre
Acesso livre

Hematologia Geral

Estudo randomizado | Em pacientes críticos hospitalizados com Covid-19, anticoagulação em dose terapêutica com heparina não resultou em melhores desfechos em comparação com a tromboprofilaxia farmacológica usual.

5 Ago, 2021 | 12:00h

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Comentários:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

 

Comentário no Twitter

 

Diretriz rápida NICE COVID-19 | Trombocitopenia trombótica imune induzida por vacina.

2 Ago, 2021 | 18:37h

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

Comunicado de imprensa: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Conteúdo relacionado: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Trombocitopenia trombótica imune induzida por vacina: o que se sabe e o que não se sabe.

2 Ago, 2021 | 18:33h

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood

Conteúdo relacionado: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Casos muito raros da síndrome de trombose com trombocitopenia (STT) após vacina AstraZeneca – A estimativa de STT após a primeira dose foi de 8,1 por milhão de vacinas; depois da segunda dose, a estimativa foi de 2,3 por milhão de vacinas.

2 Ago, 2021 | 17:05h

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet

Conteúdos relacionados:

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.

Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.

Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

 

Comentário no Twitter

 

Consenso ESC | Terapias antitrombóticas nas doenças arteriais aórticas e periféricas em 2021.

2 Ago, 2021 | 16:44h

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy – European Heart Journal

Pontos principais a lembrar: ESC Consensus on Antithrombotic Therapies in Aortic and Peripheral Artery Diseases – American College of Cardiology

 

Comentário no Twitter

 

Revisão | Complicações hemostáticas e trombóticas da doença hepática.

23 Jul, 2021 | 10:01h

The Hemostatic and Thrombotic Complications of Liver Disease – European Journal of Haematology

Estudo de coorte | Anemia falciforme e desfechos de COVID-19 – “Nossa análise estima um aumento de 4 vezes no risco de hospitalização por COVID-19 e de 2,6 vezes no risco de morte relacionada a COVID-19 em pacientes com anemia falciforme.”

21 Jul, 2021 | 09:55h

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine

Diretriz da OMS para manejo clínico da síndrome de trombose com trombocitopenia após vacinação contra coronavírus (COVID-19).

20 Jul, 2021 | 10:58h

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) – World Health Organization

Diretriz relacionada: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” E ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Opinião do especialista | Válvulas bioprotéticas e fibrilação atrial: anticoagulantes diretos ou warfarina – Até que dados conclusivos sobre pacientes com doença cardíaca reumática e aqueles com válvulas mecânicas estejam disponíveis, o uso de DOAC não é indicado.

20 Jul, 2021 | 10:43h

Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin – The Journal of Thoracic and Cardiovascular Surgery

Estudo de coorte | Aumento no risco de longo prazo para o desenvolvimento de anemia após cirurgia bariátrica – Em comparação com o grupo-controle, a incidência de anemia foi aumentada no grupo com by-pass gástrico (HR 5,05), no grupo com gastroplastia vertical (HR 2,67) e no grupo com banda gástrica (HR 2,76).

15 Jul, 2021 | 10:28h

Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.